Banner for VABYSMO Real-World Data (RWD) section.

.

Rapid Drying with VABYSMO - 
Dr. Veeral Sheth
 

Moorfields experience -
Dr. Robin Hamilton
 

Rapid Drying With VABYSMO -
Prof. Stéphanie Baillif
 

.

Rapid Drying with VABYSMO -
Dr. Veeral Sheth
 

Moorfields experience -
Dr. Robin Hamilton
 

Rapid Drying With VABYSMO -
Prof. Stéphanie Baillif
 

.

Make VABYSMO your first choice for rapid* vision gains1,2

Mean BDVA change from baseline in treatment-naive eyes†1,2

FARETINA nAMD

FARETINA DME

Bar graph of FARETINA-nAMD trial results showing change in visual acuity from baseline with Vabysmo in treatment-naive eyes.
Bar graph of FARETINA-DME trial results showing change in visual acuity from baseline by Vabysmo injection in treatment-naive eyes.

*Nominal P-value <0.05 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline VA and ≥6 months of follow-up. Assessments were captured around the -6 to +7-day window around each injection visit.

VABYSMO delivers fast* drying after 1 injection in the real world1,2

Mean CST in treatment-naive eyes†1,2

FARETINA nAMD

FARETINA DME

Bar graph of FARETINA-nAMD trial results showing mean CST improvements from baseline with Vabysmo in treatment-naive eyes.
Bar graph of FARETINA-DME trial results showing mean CST improvements from baseline with Vabysmo in treatment-naive eyes.

*FARETINA-DME: Nominal P-value <0.05 vs baseline and FARETINA-AMD: Nominal P-value <0.01 vs baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline CST measurement (0–30 days before index) between 7 February 2022 and 30 June 2023, and 2+ CST measures in ≤180 days before index and 2+ CST in 180 days post index, excluding CST measurements ≤14 days after an injection. Statistical test for change in CST from baseline.

Most patients achieve early fluid resolution with VABYSMO3

Presence of fluid in treatment-naive eyes3

MOORFIELDS nAMD

Bar graph of FARETINA-nAMD showing presence of fluid in treatment-naive eyes.

Increase clinical capacity with VABYSMO’s extended durability1,2,4

Mean number of injections after 12 months of VABYSMO in treatment-naive eyes1,2

FARETINA nAMD

FARETINA DME

Charts of the FARETINA-nAMD and DME trials. Vabysmo required approximately 2 injections in treatment-naive eyes during the last 6 months of the first year.

Make VABYSMO your first choice for rapid* vision gains1,2

Mean BDVA change from baseline in treatment-naive eyes†1,2

FARETINA nAMD

Bar graph of FARETINA-nAMD trial results showing change in visual acuity from baseline with Vabysmo in treatment-naive eyes.

FARETINA DME

Bar graph of FARETINA-DME trial results showing change in visual acuity from baseline by Vabysmo injection in treatment-naive eyes.

*Nominal P-value <0.01 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline VA and ≥6 months of follow-up. Assessments were captured around the -6 to +7-day window around each injection visit.

VABYSMO delivers fast* drying after 1 injection in the real world1,2

Mean CST in treatment-naive eyes†1,2

FARETINA nAMD

Bar graph of FARETINA-nAMD trial results showing mean CST improvements from baseline with Vabysmo in treatment-naive eyes.

FARETINA DME

Bar graph of FARETINA-DME trial results showing mean CST improvements from baseline with Vabysmo in treatment-naive eyes.

*Nominal P value <0.01 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline CST measurement (0–30 days before index) between February 7, 2022 and June 30, 2023, and 2+ CST measures in ≤180 days before index and 2+ CST in 180 days post index, excluding CST measurements ≤14 days after an injection. Statistical test for change in CST from baseline.

Most patients achieve early fluid resolution with VABYSMO3

Presence of fluid in treatment-naive eyes3

MOORFIELDS nAMD

Bar graph of FARETINA-nAMD showing presence of fluid in treatment-naive eyes.

Mean number of injections after 12 months of VABYSMO in treatment-naive eyes1,2

FARETINA nAMD

Charts of the FARETINA-nAMD and DME trials. Vabysmo required approximately 2 injections in treatment-naive eyes during the last 6 months of the first year.
Charts of the FARETINA-nAMD and DME trials. Vabysmo required approximately 2 injections in treatment-naive eyes during the last 6 months of the first year.

FARETINA DME

Charts of the FARETINA-nAMD and DME trials. Vabysmo required approximately 2 injections in treatment-naive eyes during the last 6 months of the first year.
References
  1. Tabano D, et al. Presented at ARVO 2024, presentation available at medically.roche.com.
  2. Borkar D, et al. Presented at ARVO 2024, presentation available at medically.roche.com.
  3. Sing YS, et al. Presented at EURETINA 2023.
  4. Narayan A, et al. Presented at EURETINA 2023.